Investigator Initiated Research and Grants

Accord BioPharma may provide monetary, in-kind, or other support for scientific research in response to unsolicited requests from independent researchers. This enables Accord BioPharma to contribute to the scientific understanding and body of knowledge about Accord BioPharma products and disease areas in order to enhance the practice of medicine and ultimately improve patient care.

All types of research programs will be considered for funding through Accord BioPharma’s Investigator-Initiated Research (IIR) and Grants Policy. IIRs are clinical studies that are initiated, developed, and conducted by a qualified researcher external to Accord who assumes all legal and regulatory responsibility for the research. Potential IIR programs may be funded following a rigorous review process.

Investigator Responsibilities & Expectations

Applicants awarded funding by Accord’s research grants program fulfill the role of the study sponsor and investigator. Accord fulfills the role of primary funding source. Funded sponsor-investigators are responsible for the design, management and conduct of the study, as well as maintaining compliance with all applicable laws and regulations. Accord and the sponsor-investigators will generate study-specific, progress-based milestones to align expectations and ensure timely execution of the study.

Instructions for Grant Submission

Researchers interested in applying for competitive research funding through Accord’s IIR Review Committee (IRC) should familiarize themselves with investigator expectations, Accord’s funding priorities, and the research grant review process.

The full list of responsibilities of the requestor or investigator is available by emailing

Competitive Review Process

The Accord IRC carefully evaluates applications based on the following criteria:
  • Investigator independence in proposal design and submission
  • Scientific merit
  • Adherence to ethical guidelines and patient risk assessment
  • Consistency with Accord’s scientific objectives
  • Investigator expertise and qualifications
  • Consistent with established funding priorities and fair market value
  • Availability of funding, support study drug availability
  • Use of proposed funding
  • Investigator compliance history

IIR and Unrestricted Medical Educational Grants Review Process

Start Your Application

You will be required to submit the following documentation for evaluation. Below are templates to help facilitate the review of your application.

The Accord IRC reviews applications each quarter of the calendar year. Below outlines the deadline for submission for review for the next following quarter.
LOI or Grant Submission Deadline Review Period Acknowledgement Date IIR Submission Deadline IIR Acknowledgement Date
November 1, 2023 November 30, 2023 December 15, 2023 January 15, 2024 May 15, 2024
LOI or Grant Submission Deadline: November
1, 2023
Review Period: November
30, 2023
Acknowledgement Date: December
15, 2023
IIR Submission Deadline: January
15, 2024
IIR Acknowledgement Date: May
15, 2024
You will be promptly notified of Accord’s IRC funding decision via email. If you have any questions regarding the process or would like to speak to the investigator-sponsored studies program team regarding your new or existing application, please contact us at